Compare AbCellera Biologics Inc (ABCL) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Intuitive Surgical, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Intuitive Surgical, Inc. trades at $418.64 (market cap $151.33B). The key difference: Intuitive Surgical, Inc. is far larger — about 64.4× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals.
| ABCL | ISRG | |
|---|---|---|
Market Cap | $2.35B | $151.33B |
Sector | Health | Health |
52-Week High | $8.12 | $592.85 |
52-Week Low | $2.78 | $397.68 |
Enterprise Value | $1.99B | $146.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Intuitive Surgical (ISRG) trades at $427.30, up 0.3% on the day, with a bullish technical outlook supported by moving averages and strong support at $422. The company reported robust Q1 2026 earnings of $2.50 per share, beating estimates, and has consistently exceeded expectations. Revenue grew to $10.06 billion in 2025, with a net income margin of 28.15%, though valuation multiples remain elevated with a P/E of 52.59.
The outlook is positive, driven by procedure growth guidance of 13.5-15.5% for 2026 and analyst consensus targeting $565.20. Risks include premium valuation sensitivity and reimbursement challenges in new markets like appendectomy. Institutional sentiment is bullish, with 69% of analysts rating it a buy, but investors should monitor execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
